Bio-Techne Opened New Manufacturing Facility in Bristol
The 10,000-square-foot site is designed to support cell therapy developers with GMP-grade production capabilities.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Do you trust that increased private investment in manufacturing will lower costs for advanced medical therapies?
Bio-Techne has officially opened a new small-molecule manufacturing facility in Bristol. The site provides essential production capacity for cell therapy developers from early development stages through to clinical and commercial manufacturing.
Why it matters
This expansion provides cell therapy developers with the manufacturing consistency and scalability needed to advance complex treatments. The new facility helps meet the growing production demands within the sector.
The new 10,000-square-foot Bristol facility is equipped with five ISO-8 cleanrooms and two ISO-7 cleanrooms. These specialized environments allow for precise manufacturing and product handling for cell therapy developers.
The players
Bio-Techne
Bio-Techne is a global life sciences company that develops and manufactures high-quality purified proteins and reagent solutions for research and clinical diagnostic use.
The details
The facility is now fully operational and dedicated to producing high-quality materials for cell therapy research and development. It integrates into the company broader network that currently includes recombinant protein manufacturing in Minneapolis and GMP sites in St Paul.
Timeline
Bio-Techne announced the opening of the Bristol facility on October 13, 2026.
The Tech Race
The opening of this facility follows a pattern set by the cell therapy manufacturing standard of ensuring dedicated, high-grade cleanroom environments. It positions the company to compete directly in the expanding market for outsourced clinical and commercial production.
The new facility strengthens the local supply chain for specialized medical materials, potentially accelerating the development timelines for therapeutic treatments. For the average resident, it represents an investment in the local life sciences sector and industrial growth.
The takeaway
The addition of this facility provides a critical boost to the consistency and scale of cell therapy production. Biotech developers can now rely on additional GMP-grade capacity to bring their clinical programs to market more efficiently.
Further reading
Learn more about the latest developments in the sector on our Biotech page.
Live Poll
Do you trust that increased private investment in manufacturing will lower costs for advanced medical therapies?
